Aeris Capital

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.

Solstice Biologics LLC is a biotechnology company focused on developing small, cell-permeable RNA interference (RNAi) pro-drugs aimed at enhancing the targeting and delivery of nucleic acid therapeutics. Founded in 2012 and based in San Diego, California, the company specializes in creating innovative solutions that allow for the effective entry of therapeutic agents into various cell types. By utilizing small double-stranded cellular RNA to selectively degrade specific messenger RNAs, Solstice Biologics addresses critical challenges in the field of RNAi therapeutics, facilitating the advancement of new treatments.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.

Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.

Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.

Smaato Inc. is a global advertising technology company that specializes in real-time advertising solutions for mobile publishers, application developers, and advertisers. Founded in 2005 and headquartered in San Francisco, with additional offices in Hamburg and Singapore, Smaato operates the SPX platform, an enterprise-level ad server that simplifies mobile monetization for its clients. This platform integrates various demand and supply sources, allowing publishers to manage their inventory and utilize first-party data effectively. By connecting quality publishers with premium marketers, Smaato enables clients to enhance their revenue potential and engage audiences across multiple devices.

Sonetik AG is a Swiss company based in Bern that specializes in developing and offering digital hearing aids for individuals with hearing impairments. The company provides a range of preset hearing aids tailored to the most common patterns of hearing loss, including variants designed for slightly sloping, steeply sloping, high frequency, and flat losses. By utilizing a specialized software system, Sonetik's hearing aids can be effectively matched to individuals' hearing loss profiles established through a hearing test, often eliminating the need for further adjustments by an audiologist. This approach allows Sonetik to offer high-quality hearing solutions at a significantly lower cost, making them accessible to a wider audience. Sonetik operates as a subsidiary of Harvard International plc.

Invincea, Inc. is a cybersecurity company based in Fairfax, Virginia, specializing in advanced endpoint security software solutions. Founded in 2006 and originally known as Secure Command, LLC, Invincea rebranded in 2010 and has since positioned itself as a leader in endpoint threat protection, serving over 25,000 customers and 3 million active users across various sectors, including education, finance, healthcare, and utilities. The company's flagship product, X by Invincea, leverages machine learning and behavioral monitoring to detect and neutralize sophisticated cyber threats, such as spear phishing and drive-by downloads, without compromising user productivity. Invincea's innovative technology, which originated from DARPA-funded research, has garnered multiple awards for its effectiveness in countering advanced attacks that evade traditional security measures. Additionally, Invincea collaborates with Dell to provide a customized version of its endpoint security solution for commercial PCs and tablets, further extending its market presence and impact. As of 2017, Invincea operates as a subsidiary of Sophos Group plc.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Atlantium Technologies Ltd., established in 2003, specializes in UV water treatment solutions for industrial and municipal applications. Its innovative products, including medium pressure UV lamps, real-time monitoring software, and quartz disinfection chambers, enable chemical-free disinfection, de-chlorination, and RO membrane protection. Serving clients in aquaculture, bio-pharma, food and beverage, power and energy, and municipal markets, Atlantium's solutions provide sustainable, measurable water treatment options, with global installations including Fortune-500 companies. The company, headquartered in Beit Shemesh, Israel, offers dedicated customer support through strategically placed service centers.

Solstice Biologics LLC is a biotechnology company focused on developing small, cell-permeable RNA interference (RNAi) pro-drugs aimed at enhancing the targeting and delivery of nucleic acid therapeutics. Founded in 2012 and based in San Diego, California, the company specializes in creating innovative solutions that allow for the effective entry of therapeutic agents into various cell types. By utilizing small double-stranded cellular RNA to selectively degrade specific messenger RNAs, Solstice Biologics addresses critical challenges in the field of RNAi therapeutics, facilitating the advancement of new treatments.

Crescendo Bioscience, Inc. is a molecular diagnostics company based in South San Francisco, California, that specializes in developing quantitative diagnostic tools for rheumatologists managing autoimmune and inflammatory diseases. Founded in 2002, the company focuses on creating and commercializing blood tests, notably Vectra DA, a standardized multi-biomarker test that assesses disease activity in rheumatoid arthritis. These diagnostic and prognostic tools provide physicians with crucial clinical insights, facilitating therapy selection, monitoring, and overall management of patients with rheumatoid arthritis. By offering objective molecular tests and disease information services, Crescendo Bioscience aims to improve patient outcomes in the field of rheumatology.

Solstice Biologics LLC is a biotechnology company focused on developing small, cell-permeable RNA interference (RNAi) pro-drugs aimed at enhancing the targeting and delivery of nucleic acid therapeutics. Founded in 2012 and based in San Diego, California, the company specializes in creating innovative solutions that allow for the effective entry of therapeutic agents into various cell types. By utilizing small double-stranded cellular RNA to selectively degrade specific messenger RNAs, Solstice Biologics addresses critical challenges in the field of RNAi therapeutics, facilitating the advancement of new treatments.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.

Nanosolar, Inc. is a manufacturer of solar electricity cells and panels, focusing on cost-efficient solar energy solutions. Founded in 2001 and headquartered in San Jose, California, with additional manufacturing facilities in Berlin, Germany, the company produces products such as the Utility Panel, designed for utility-scale power plants, and SolarPly, a lightweight solar-electric cell foil that can be customized to various sizes. Nanosolar employs a proprietary printing technique for CIGS (Copper, Indium, Gallium, Selenium) solar cells, utilizing nanoparticle inks and an annealing process. This innovative approach reduces reliance on expensive high vacuum deposition equipment, allowing the company to leverage industrial printing and roll-to-roll manufacturing technologies to produce solar-electric foil efficiently and at high speeds.

Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Crescendo Bioscience, Inc. is a molecular diagnostics company based in South San Francisco, California, that specializes in developing quantitative diagnostic tools for rheumatologists managing autoimmune and inflammatory diseases. Founded in 2002, the company focuses on creating and commercializing blood tests, notably Vectra DA, a standardized multi-biomarker test that assesses disease activity in rheumatoid arthritis. These diagnostic and prognostic tools provide physicians with crucial clinical insights, facilitating therapy selection, monitoring, and overall management of patients with rheumatoid arthritis. By offering objective molecular tests and disease information services, Crescendo Bioscience aims to improve patient outcomes in the field of rheumatology.

SynapSense specializes in wireless instrumentation solutions aimed at enhancing energy efficiency and reducing carbon footprints for data centers and enterprises. The company offers environmental data and energy analysis services that assist data center managers in optimizing operations and minimizing pollution. By providing these comprehensive tools, SynapSense enables clients to achieve significant improvements in sustainability and operational performance.

Smaato Inc. is a global advertising technology company that specializes in real-time advertising solutions for mobile publishers, application developers, and advertisers. Founded in 2005 and headquartered in San Francisco, with additional offices in Hamburg and Singapore, Smaato operates the SPX platform, an enterprise-level ad server that simplifies mobile monetization for its clients. This platform integrates various demand and supply sources, allowing publishers to manage their inventory and utilize first-party data effectively. By connecting quality publishers with premium marketers, Smaato enables clients to enhance their revenue potential and engage audiences across multiple devices.

Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.

Smaato Inc. is a global advertising technology company that specializes in real-time advertising solutions for mobile publishers, application developers, and advertisers. Founded in 2005 and headquartered in San Francisco, with additional offices in Hamburg and Singapore, Smaato operates the SPX platform, an enterprise-level ad server that simplifies mobile monetization for its clients. This platform integrates various demand and supply sources, allowing publishers to manage their inventory and utilize first-party data effectively. By connecting quality publishers with premium marketers, Smaato enables clients to enhance their revenue potential and engage audiences across multiple devices.

Coda Automotive builds eco-friendly transportation -- chiefly electric cars -- to create a livable future for generations to come. Headquartered in Southern California, CODA Automotive teamed with American partners to develop an American designed and manufactured electric drivetrain as well as battery system electronics to serve as the foundation for the CODA car. They also partnered with the most highly proficient and advanced companies from around the world, from China to Europe, to build a safe and affordable all-electric car. All the while, CODA Automotive maintained control of brand, design, and critical intellectual property.

Livescribe, Inc. is a company specializing in the design, manufacture, and marketing of smartpens that enable users to capture, search, and share handwritten notes in digital formats. Founded in 2007 and based in Oakland, California, Livescribe's products include the Sky Wi-Fi smartpen, which transfers notes and audio to digital accounts for access on various devices, the Echo smartpen that connects via USB to transfer notes, and the Livescribe 3 smartpen, which uses Bluetooth for data transfer to smartphones and tablets. These smartpens are particularly beneficial for college students, individuals with learning disabilities, educational institutions, and professionals such as journalists. In addition to smartpens, the company offers dot paper, ink, and accessories for purchase online. Livescribe also operates as a subsidiary of Anoto Group AB, further expanding its reach in the mobile computing market.

Coda Automotive builds eco-friendly transportation -- chiefly electric cars -- to create a livable future for generations to come. Headquartered in Southern California, CODA Automotive teamed with American partners to develop an American designed and manufactured electric drivetrain as well as battery system electronics to serve as the foundation for the CODA car. They also partnered with the most highly proficient and advanced companies from around the world, from China to Europe, to build a safe and affordable all-electric car. All the while, CODA Automotive maintained control of brand, design, and critical intellectual property.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.

Mode Media, founded in Silicon Valley in 2004, is a top 10 U.S. media property with 136 million unique users a month. The company aims to help people discover relevant content by combining human curation with technology that distributes content to the right audience at the right time. Mode Media is focused on building the largest independent premium video and content platform for creators, utilizing distribution and streaming technology to deliver targeted native videos, content, and branded entertainment in real-time. With Mode.com as its owned social networking platform, creators can upload videos and create content stories that are curated by professional editors and personalized through the Mode content algorithm technology. Within six months of its launch, Mode has attracted 31 million unique monthly users and has exceeded 1 billion streamed video views.

Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.

Smaato Inc. is a global advertising technology company that specializes in real-time advertising solutions for mobile publishers, application developers, and advertisers. Founded in 2005 and headquartered in San Francisco, with additional offices in Hamburg and Singapore, Smaato operates the SPX platform, an enterprise-level ad server that simplifies mobile monetization for its clients. This platform integrates various demand and supply sources, allowing publishers to manage their inventory and utilize first-party data effectively. By connecting quality publishers with premium marketers, Smaato enables clients to enhance their revenue potential and engage audiences across multiple devices.

Tethys BioScience, Inc. is focused on the discovery, development, and commercialization of biological markers for diagnosing metabolic diseases, particularly diabetes. The company has developed the PreDx Diabetes Risk Test, which evaluates a combination of proteins and other blood-borne biomarkers associated with diabetes risk. Founded in 2002, Tethys BioScience is headquartered in Emeryville, California.

Adamas Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of medicines for chronic neurologic disorders. Headquartered in Emeryville, California, the company offers GOCOVRI, an extended-release capsule designed to treat dyskinesia in patients with Parkinson's disease who are undergoing levodopa-based therapy. Adamas is also advancing the development of ADS-5102, currently in Phase III clinical studies targeting walking impairment in patients with multiple sclerosis, and ADS-4101, which has completed Phase I studies for partial onset seizures in epilepsy. Additionally, Adamas provides Namzaric, a combination therapy for moderate to severe Alzheimer's dementia. Founded in 2000, the company operates primarily in the United States, with a focus on addressing healthcare challenges associated with central nervous system disorders.

ConforMIS is a medical technology company based in the United States that specializes in joint replacement implants and instruments. Utilizing its proprietary iFit® Image-to-Implant® technology platform, ConforMIS develops and manufactures personalized implants that are uniquely sized and shaped to match each patient's anatomy. The company's offerings include a wide range of sterile knee and hip implants, such as partial and total knee replacements, along with single-use surgical instruments. ConforMIS's iFit technology encompasses design, printing, and just-in-time delivery, allowing for customized solutions that enhance patient outcomes. The company primarily generates revenue through sales to hospitals and ambulatory surgical centers, positioning itself within the knee replacement market.

ConforMIS is a medical technology company based in the United States that specializes in joint replacement implants and instruments. Utilizing its proprietary iFit® Image-to-Implant® technology platform, ConforMIS develops and manufactures personalized implants that are uniquely sized and shaped to match each patient's anatomy. The company's offerings include a wide range of sterile knee and hip implants, such as partial and total knee replacements, along with single-use surgical instruments. ConforMIS's iFit technology encompasses design, printing, and just-in-time delivery, allowing for customized solutions that enhance patient outcomes. The company primarily generates revenue through sales to hospitals and ambulatory surgical centers, positioning itself within the knee replacement market.

mobileo was founded with the aim of "distributing relevant content on the mobile Internet". The company was based in Hamburg (Germany) , and founded by Freddie Geier, former head of Apple Germany. As a main line for its development, mobileo wanted to enable a channel of distribution for content providers on the mobile internet, focusing around a core element, the location. In particular mobileo was very keen on providing a solution for the publishing industry in regards to the challenge of mobility, as well as on allowing the end user to contribute through the sharing of her/his favorite locations. A complete ecosystem was developed consisting of import (and normalization) components, a storage system, a server component, and mobile clients. All along this processing chain, usage was made of an internally developed technology, enabling the expression of relevance (where, when, what) for the content aggregation. This ecosystem was the foundation for both products for external customers, as well as for an own consumer product, GRYD. On the day of the launch of their consumer platform, GRYD, mobileo had to file bankruptcy due to the reason that the investor didn't fulfill is obligations.

Smaato Inc. is a global advertising technology company that specializes in real-time advertising solutions for mobile publishers, application developers, and advertisers. Founded in 2005 and headquartered in San Francisco, with additional offices in Hamburg and Singapore, Smaato operates the SPX platform, an enterprise-level ad server that simplifies mobile monetization for its clients. This platform integrates various demand and supply sources, allowing publishers to manage their inventory and utilize first-party data effectively. By connecting quality publishers with premium marketers, Smaato enables clients to enhance their revenue potential and engage audiences across multiple devices.